ImmunityBio
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2014-01-01
- Employees
- 628
- Market Cap
- $2.9B
- Website
- http://www.immunitybio.com
- Introduction
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.
Clinical Trials
72
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (69 trials with phase data)• Click on a phase to view related trials
Open Label, Phase 2 Study of CD19t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma.
- Conditions
- Relapsed B-Cell Non Hodgkin Lymphoma
- Interventions
- Biological: CD19 t-haNK- IV Administration
- First Posted Date
- 2025-08-15
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT07125872
A Study to Examine Anktiva for the Treatment of COVID-19.
- Conditions
- Long COVIDLong COVID SyndromeLong Covid 19
- Interventions
- First Posted Date
- 2025-08-14
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT07123727
- Locations
- 🇺🇸
Chan Soon-Schiong Institute for Medicine (CSSIFM), El Segundo, California, United States
A Study to Assess Anktiva in Patients With Long Covid-19.
- Conditions
- Long COVID
- Interventions
- Drug: N-803 (IL-15 Superagonist)
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT07108036
- Locations
- 🇺🇸
University of California - San Francisco, San Francisco, California, United States
Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy
- Conditions
- Lymphopenia
- First Posted Date
- 2025-05-04
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT06956547
- Locations
- 🇺🇸
Chan Soon - Shiong Institute for Medicine, El Segundo, California, United States
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
- Conditions
- Non-muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- Drug: N-803 and Gemcitabine
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06829823
- Prev
- 1
- 2
- 3
- 4
- 5
- 15
- Next
News
ANKTIVA Reverses Lymphopenia and Extends Survival in Checkpoint Inhibitor-Resistant Lung Cancer
ImmunityBio's Phase 2 QUILT-3.055 study demonstrates that ANKTIVA reverses lymphopenia in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer.
Novel Immunotherapy Combination Achieves 100% Disease Control in Recurrent Glioblastoma Pilot Study
A chemotherapy-free regimen combining nogapendekin alfa (Anktiva), NK cell therapy, and tumor treating fields achieved 100% disease control in five recurrent glioblastoma patients.
ImmunityBio Launches Phase 2 Trial of ANKTIVA for Long COVID Treatment
ImmunityBio has initiated a Phase 2 study evaluating ANKTIVA (nogapendekin alfa inbakicept-pmln) as a potential treatment for long COVID, marking the first clinical trial of an IL-15 agonist for this indication.
ImmunityBio's CD19 CAR-NK Therapy Achieves Complete Responses in Late-Stage Waldenstrom Macroglobulinemia
ImmunityBio's QUILT-106 Phase I trial demonstrated complete responses in the first two heavily pretreated Waldenstrom macroglobulinemia patients using CD19 CAR-NK cell therapy.
ImmunityBio Partners with Saudi Arabia to Bring FDA-Approved Cancer BioShield Platform to Middle East
ImmunityBio signed a strategic MOU with Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC to introduce the FDA-approved Cancer BioShield platform to the Middle East region.
FDA Rejects ImmunityBio's Expanded Anktiva Application While Lifting Hold on Atara's Ebvallo Trials
ImmunityBio received an FDA "refusal to file" letter for its application to expand Anktiva's use in bladder cancer patients, causing a 25% stock plunge and prompting calls for agency clarification.
ImmunityBio Settles $10.5M Lawsuit Over FDA Rejection of Cancer Drug Anktiva
ImmunityBio agreed to pay $10.5 million to settle investor claims that the company misled shareholders about manufacturing deficiencies that led to FDA rejection of its cancer drug Anktiva.
ImmunityBio Secures $75 Million in Equity Financing to Advance Immunotherapy Pipeline
ImmunityBio has executed a $75 million registered direct offering with a single institutional investor, providing crucial working capital for its ongoing operations.
ImmunityBio Achieves Multiple Milestones in Q1 2024, Advances ANKTIVA Development with RMAT Designation
• ImmunityBio reports significant progress with ANKTIVA's approval and permanent J-code assignment for treating BCG-unresponsive bladder cancer CIS, marking a major advancement in treatment options. • The company receives RMAT designation from FDA for ANKTIVA + PD-L1 t-haNK combination therapy for lymphopenia reversal, potentially transforming immunotherapy treatment approaches. • Strategic developments include EMA and MHRA submission acceptance, BeOne collaboration for checkpoint inhibitor supply, and expanded access to recombinant BCG amid TICE BCG shortage.
FDA Grants ImmunityBio Authorization to Supply Recombinant BCG Amid TICE BCG Shortage
ImmunityBio receives FDA authorization to provide recombinant BCG (rBCG) to urologists, addressing the critical TICE BCG shortage for bladder cancer treatment.